Premium
MRI evolution of new MS lesions enhancing after different doses of gadolinium
Author(s) -
Rovaris M.,
Mastronardo G.,
Gasperini C.,
Prandini F.,
Yousry T. A.,
Filippi M.
Publication year - 1998
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1998.tb01725.x
Subject(s) - gadolinium , multiple sclerosis , medicine , nuclear medicine , magnetic resonance imaging , gadolinium dtpa , radiology , chemistry , organic chemistry , psychiatry
Objective ‐ To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium‐DTPA (Gd). Material and methods ‐ For 3 months, 30 relapsing‐remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd‐enhanced T 1 weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow‐up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month. Results ‐ In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P <0.005) were not enhancing, 16 (18%; P <0.01) were still enhancing only after TD and 14 (15%; P =NS) showed enhancement after both SD and TD. Conclusion ‐Enhancing lesions in patients with MS are heterogeneous. Those enhancing only after TD of Gd are characterized by a milder and shorter opening of the blood‐brain barrier.